PI3K/mTOR inhibitor

PI-103 is a potent ATP-competitive dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mTOR (mammalian target of rapamycin).

PI3K, an important intracellular mediator, regulates multiple cellular functions including cell growth and survival. PI3K activates a number of downstream targets including the serine/threonine kinase Akt that activates mTOR, the master negative regulator of autophagy.

By inhibiting mTOR activity, PI‑103 induces autophagy and promotes cell survival [1, 2]. Conversely, combining PI‑103 with inhibitors of autophagy, such as 3-methyladenine or bafilomycin A1, leads to apoptosis [1].


Solubility: 10 mg/ml (28.7 mM) in DMSO
Synonym: 3-[4-(4-Morpholinylpyrido[3’,2’:4,5]furo[3,2-d]pyrimidin-2-yl]phenol hydrochloride
CAS number: 371935-74-9
Molecular weight:
≥97% (UHPLC)
Working Concentration:
0.1-10 μM


• 5 mg PI-103

PI-103 is provided as a solid and shipped at room temperature. Store at -20 °C.


1. Fan QW. & Weiss W., 2011. Autophagy and Akt promote survival in glioma. Autophagy7(5): 536-8.
2. Park S. et al., 2008. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML.Leukemia. 22(9):1698-706.



Description PI3K/mTOR inhibitor
Cat. Codeinh-pi10
Unit Size5 mg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "www.invivogen.com".